Core Insights - PharmaTher Holdings Ltd. has received FDA approval for KETARx™, positioning the company for market entry and expansion into rare disorders [2][3] - The company aims to establish a strong ketamine franchise focusing on surgical and diagnostic anesthesia, while also pursuing additional therapeutic applications [2][4] - The global ketamine injectable market is projected to grow from $725 million in 2024 to $3.42 billion by 2034, indicating significant market potential [4] Commercialization Strategy - PharmaTher is implementing a comprehensive strategy for KETARx™ aimed at sustainable growth through strategic partnerships and self-launch capabilities [3][5] - The company is in advanced discussions with specialty pharmaceutical partners to accelerate U.S. and international launches, with a definitive agreement expected by Q4-2025 [5][6] - If no partnership is secured, PharmaTher plans to self-launch KETARx™ leveraging established manufacturing and commercial partners [5] Market Opportunity - The U.S. market has approximately 50-55 million surgical procedures and 23-24 million diagnostic procedures annually that utilize anesthesia, representing high-value access points for KETARx™ [4] - The increasing number of surgical and diagnostic procedures, driven by an aging population and rising chronic diseases, creates robust demand for KETARx™ [4] - The FDA's increasing openness to real-world evidence supports a fast-follower strategy under the 505(b)(2) pathway for rare disorders [4][7] Regulatory Pathway - PharmaTher is pursuing additional FDA approvals for KETARx™ to address rare disorders, leveraging orphan drug designations to enhance market exclusivity [7][8] - The company plans to submit a New Drug Application (NDA) for Complex Regional Pain Syndrome (CRPS) by the end of Q4-2025, with a potential Prescription Drug User Fee Act (PDUFA) date by Q4-2026 [8][9] - PharmaTher holds five FDA orphan drug designations for ketamine, each representing distinct opportunities for market exclusivity [8] Future Plans - The company intends to submit another NDA for KETARx™ to treat a different rare disorder by Q1-2026, with details to be released closer to the filing [10] - PharmaTher is strategically focused on advancing ketamine for rare disorders, avoiding non-orphan indications to maintain competitive advantages [11]

Core Viewpoint - PharmaTher Holdings Ltd. has received FDA approval for its ketamine product KETARx™ for surgical pain management, marking a significant milestone for the company and the potential for future growth in the pharmaceutical market [1][2]. Group 1: FDA Approval and Market Impact - The FDA approval for KETARx™ is described as a turning point for PharmaTher, indicating a new era of opportunities for the company and its shareholders [2]. - The company is moving quickly into pre-launch commercialization of KETARx™ in the U.S. and is preparing for international regulatory filings [3]. - There is an immediate surge of interest from specialty pharmaceutical companies, indicating a strong market response to the approval [3]. Group 2: Commercialization Strategy - Partnership discussions are already underway, and the company is advancing its commercial plan to launch KETARx™ within the year [4]. - The sales strategy targets hospitals, specialty clinics, and government institutions, including the U.S. Department of Defense and Veterans Health Administration [4]. - The company emphasizes that this is only the first phase, with millions of surgical patients set to benefit from KETARx™ [5]. Group 3: Future Potential and Pipeline - The FDA approval reinforces the company's mission to unlock the full pharmaceutical potential of ketamine for various disorders, including mental health and pain conditions [6]. - The company is exploring additional clinical-stage programs under the FDA's 505(b)(2) pathway, which could expand its market reach [7]. - The pipeline includes treatments for conditions such as Parkinson's disease, ALS, and CRPS, as well as innovative delivery methods like a ketamine patch and wearable pump [9]. Group 4: Vision and Commitment - PharmaTher's vision since its founding in April 2020 has been to focus entirely on ketamine, culminating in the recent FDA approval [8]. - The company aims to build itself into a leader in next-generation ketamine therapeutics, with a commitment to innovation and global expansion [10][11].

PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM)) August 14, 2025 8:00 AM EDT | Source: PharmaTher Holdings Ltd. Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has ...

Core Viewpoint - PharmaTher Holdings Ltd. has received FDA approval for its ketamine product KETARx™, marking a significant milestone in the company's efforts to become a leader in ketamine-based pharmaceuticals and contributing to the psychedelic pharmaceutical revolution [1][2]. Company Summary - The FDA approved KETARx™ on August 8, 2025, for surgical pain management, which positions PharmaTher strategically in the market [1]. - The company aims to leverage this approval to expand its product pipeline into various therapeutic areas, including mental health, neurological disorders, and chronic pain management [3]. - CEO Fabio Chianelli emphasized that this approval is a testament to years of development and signals a new era of growth for PharmaTher [2]. Industry Summary - Ketamine is the only psychedelic drug listed on the World Health Organization's Model List of Essential Medicines, highlighting its importance in the pharmaceutical landscape [2]. - The global ketamine market is currently valued at $750 million and is projected to grow to $3.42 billion by 2034, with a compound annual growth rate of 16.4% [2]. - SPRAVATO® (esketamine), an FDA-approved treatment for depression, is on track for a sales run rate of $1.6 billion, with expectations of reaching $3 billion to $3.5 billion by 2027-2028 [2]. - The FDA's approval of KETARx™ comes amid ongoing drug shortages, indicating a significant demand for a reliable supply of ketamine [4]. - The Veterans Health Administration is currently funding ketamine infusions for veterans suffering from depression, PTSD, and chronic pain, further underscoring the therapeutic potential of ketamine [4].

Core Insights - The U.S. FDA has approved PharmaTher's ketamine product, KETARx™, for surgical pain management, marking a significant milestone for the company and positioning it within the psychedelic pharmaceutical sector [1][2][3] Company Overview - PharmaTher Holdings Ltd. aims to become a global leader in ketamine-based pharmaceuticals, focusing on mental health, neurological, and pain disorders [2][5] - The company has a strong commitment to developing ketamine for various therapeutic areas, including depression, Parkinson's disease, ALS, and chronic pain management [3] Market Potential - The global ketamine market is currently valued at $750 million and is projected to grow to $3.42 billion by 2034, reflecting a compound annual growth rate (CAGR) of 16.4% [2] - SPRAVATO® (esketamine), an FDA-approved treatment for depression, is on track for sales of $1.6 billion, with expectations of reaching $3 billion to $3.5 billion by 2027-2028, highlighting the market's potential for KETARx™ [2] Regulatory Context - The FDA's approval of KETARx™ provides a foundation for expanding ketamine's development across various therapeutic areas, addressing a significant need for a consistent, high-quality supply of ketamine [3][4] - The FDA has recognized the importance of expanding research and access to psychedelic therapies, particularly for veterans suffering from mental health issues [4]